162 related articles for article (PubMed ID: 38572536)
1. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
4. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
6. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
7. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
8. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
[No Abstract] [Full Text] [Related]
9. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Clin Endocrinol (Oxf); 2020 Jan; 92(1):71-76. PubMed ID: 31663136
[TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
11. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
[TBL] [Abstract][Full Text] [Related]
12. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
[TBL] [Abstract][Full Text] [Related]
13. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
14. Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
Fukuda N; Toda K; Ohmoto A; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Anticancer Res; 2021 Mar; 41(3):1683-1691. PubMed ID: 33788766
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
16. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract][Full Text] [Related]
20. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H
Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
